

***APOE-ε4*, white matter hyperintensities, and cognition in Alzheimer and Lewy body dementia**

Saira Saeed Mirza, MD, PhD^{1,2}, Usman Saeed, MSc^{3,4}, Jo Knight, PhD⁵, Joel Ramirez, PhD^{2,4,6}, Donald T. Stuss, PhD^{1,2,7,8}, Julia Keith, MD⁹, Sean M. Nestor, MD, PhD^{4,10}, Di Yu, MSc^{2,4,6,11}, Walter Swardfager, PhD^{2,4,6,11}, Ekaterina Rogaeva, PhD¹², Peter St. George Hyslop, MD^{12,13}, Sandra E. Black, MD^{1,2,3,4,6,7,14†}, Mario Masellis, MD, PhD^{1,2,3,4†}, and Alzheimer's Disease Neuroimaging Initiative*

†Contributed equally as senior co-authors

*Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found in the supplement file.

1. Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada
2. Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada
3. Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
4. LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada
5. Data Science Institute and Medical School, Lancaster University, Lancaster, UK

6. Heart and Stroke Foundation Canadian Partnership for Stroke Recovery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
7. Rehabilitation Sciences Institute, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
8. Department of Psychology, Faculty of Arts and Science; University of Toronto, Toronto, ON, Canada
9. Department of Anatomic Pathology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada
10. Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, ON, Canada
11. Department of Pharmacology & Toxicity, University of Toronto, Toronto, ON, Canada
12. Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada
13. Cambridge Institute for Medical Research, Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK
14. Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada

Corresponding author: Saira Saeed Mirza

Post-doctoral fellow, Division of Neurology, Department of Medicine

Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute

University of Toronto, Toronto, ON, Canada

Email: saira.mirza@sunnybrook.ca; saira.mirza@mail.utoronto.ca

Phone: +1 (416) 480 6100. Extension: 85420

Statistical analyses were performed by the first/corresponding author

Title: 89 characters

Word count: Abstract 247 (~250); text 4,468 (~4,500)

Tables: 7 (~7); References: 50 (~50)

Disclosures:

Dr. Mirza, Mr. Saeed, Dr. Knight, Dr. Ramirez, Dr. Stuss, Dr. Keith, Dr. Nestor, Ms. Yu, Dr. Rogaeva, and Dr. St. George Hyslop report no disclosures. Dr. Swardfager is funded by Alz Soc US and Brain Canada. Dr. Black reports personal fees for CME from Medscape/Biogen, Eli Lilly, Novartis; for ad-hoc consulting from Novartis, Merck, Eli Lilly and Pfizer; contract grants to the institution from GE Healthcare, Eli Lilly, Biogen Idec, Novartis, Genentech, Roche, and Optina.. Dr. Masellis reports personal fees for ad hoc consultancy from Arkuda Therapeutics, Ionis Pharmaceuticals, and Alector Pharmaceuticals, royalties from Henry Stewart Talks Ltd., and grants to the institution from Roche, Novartis, Washington University, and Axovant Sciences.

Study funding:

This work was supported by Canadian Institutes of Health Research grant (MOP13129) to M.M. and S.E.B, and an Early Researcher Award to M.M. from the Ministry of Research, Innovation, and Science (MRIS; Ontario).

Search Terms: [26] Alzheimer’s Disease; [28] Dementia with Lewy Bodies; [206] Executive function

ABSTRACT

Objective: To determine if *APOE*- ϵ 4 influences the association between white matter hyperintensities (WMH) and cognitive impairment in Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Methods: 289 patients (AD=239; DLB=50) underwent volumetric MRI, neuropsychological testing, and *APOE*- ϵ 4 genotyping. Total WMH volumes were quantified. Neuropsychological test scores were included in a confirmatory factor analysis (CFA) to identify cognitive domains encompassing attention/executive functions, learning/ memory, and language, and factor scores for each domain were calculated per participant. After testing interactions between WMH and *APOE*- ϵ 4 in the full sample, we tested associations of WMH with factor scores using linear regression models in *APOE*- ϵ 4 carriers ($n=167$) and non-carriers ($n=122$). We hypothesized that greater WMH volume would relate to worse cognition more strongly in *APOE*- ϵ 4 carriers. Findings were replicated in 198 AD patients from the Alzheimer's Disease Neuroimaging Initiative (ADNI-I), and estimates from both samples were meta-analyzed.

Results: A significant interaction was observed between WMH and *APOE*- ϵ 4 for language, but not for memory or executive functions. Separate analyses in *APOE*- ϵ 4 carriers and non-carriers showed that greater WMH volume was associated with worse attention/executive functions, learning/memory, and language in *APOE*- ϵ 4 carriers only. In ADNI-I, greater WMH burden was associated with worse attention/executive functions and language in *APOE*- ϵ 4 carriers only. No significant associations were observed in non-carriers. Meta-analyses showed that greater WMH volume was associated with worse performance on all cognitive domains in *APOE*- ϵ 4 carriers only.

Conclusion: *APOE*- ϵ 4 may influence the association between WMH and cognitive performance in patients with AD and DLB.

Keywords: *APOE*- ϵ 4, Alzheimer's disease, Dementia with Lewy bodies, white matter hyperintensities, small vessel disease

INTRODUCTION

White matter hyperintensities (WMH) observed on structural MRI indicate cerebral small vessel disease (SVD) in most cases,¹ are risk factors for cognitive impairment and Alzheimer's disease (AD),^{2,3} and are prevalent in dementia with Lewy bodies (DLB).^{4,5} However, observed cognitive performance clinically does not always reflect the severity of the WMH burden.^{6,7}

There are several reasons for the complex association between WMH and cognition: the etiology of WMH is heterogeneous, including vascular compromise and ischemia, venous collagenosis, leading to vasogenic edema,^{8,9} cerebral amyloid angiopathy (CAA), or a combination of these,¹⁰ and genetic vulnerability to neurodegeneration.

The *APOE*- ϵ 4 allele is the strongest known genetic risk factor for sporadic AD, and is a risk factor for DLB^{11,12}, CAA,¹³ and SVD.¹⁴ Despite these associations, it remains unknown if *APOE*- ϵ 4 modulates the relationship between WMH and cognition across the dementias, i.e. if *APOE*- ϵ 4 is an effect modifier in this association.

Therefore, we examined the role of *APOE*- ϵ 4 on the association between WMH and cognitive domains in AD and DLB patients with varying degrees of SVD. We tested associations with domain-specific cognitive impairment instead of global cognition because at different disease stages, impairment might be more apparent in certain domains and not others. We hypothesized that (i) higher WMH burden would be more strongly associated with worse cognition in *APOE*- ϵ 4 carriers than non-carriers and the association would be *APOE*- ϵ 4 allele dosage dependent, (ii) this association would be irrespective of the clinical diagnosis, and (iii) if indeed WMH burden is associated with worse cognition in *APOE*- ϵ 4 carriers, WMH in carriers might be a result of a more toxic vascular pathology, i.e. CAA.

METHODS

This is a cross-sectional study examining the effect of *APOE*- ϵ 4 on the association of WMH volume and cognitive functions in patients with AD and DLB.

Setting

This work was embedded within the Sunnybrook Dementia Study (SDS)— a prospective observational study of dementia patients.¹⁵ The majority of participants in the SDS are Caucasian of European descent.

For replication of study findings, data from the Alzheimer’s Disease Neuroimaging Initiative-Phase I (ADNI-I) (2002-2004) were utilized (adni.loni.usc.edu).¹⁶ ADNI was launched in 2003 as a public-private partnership. For the most up to date information, please see www.adni-info.org.

ADNI-I is characterized by a low WMH burden ($<10 \text{ cm}^3$) at recruitment and cognitive impairment is largely attributed to AD pathology with minimal confounding comorbid SVD. The SDS represents a heterogeneous “real-world” clinical case series followed longitudinally, and reflects a similar vascular risk factor and SVD burden profile to community and population-based studies.¹⁷

Standard Protocol Approvals, Registrations, and Patient Consents

SDS (ClinicalTrials.gov: NCT01800214) is approved by the local Research Ethics Board at Sunnybrook Health Sciences Centre and written informed consent was obtained from participants or their surrogate caregivers according to the Declaration of Helsinki.

Study samples

SDS sample: Data from 289 MRI-confirmed stroke-free dementia patients, including *APOE-ε4* genotype, MRI volumetrics and neuropsychological battery were available. This included 239 AD and 50 DLB patients with varying degrees of SVD. Of the 289 patients included, 36 had autopsy data available.

ADNI-I (Replication sample): 198 AD patients with *APOE-ε4* genotype, MRI volumetric and neuropsychological data available were included. We used data from the 24 month follow-up visit instead of baseline for better comparability to the SDS sample given the mild initial nature of participants included in ADNI, i.e. progression of the AD stage and that of WMH burden, and ensuring a sufficient number of participants to obtain valid estimates.

Diagnosis of dementia

For both study samples, AD was diagnosed on recruitment, using the Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria,¹⁸ while DLB (SDS only) was diagnosed using the Third Report of DLB Consortium criteria.¹⁹ Diagnoses were confirmed on clinical follow-up.

Diagnostic consensus in the SDS was achieved through review by at least two physicians (MM, NH, and SEB) with expertise in dementia diagnosis.

APOE-ε4 genotyping

APOE genotyping was performed using DNA extracted from leukocytes in both the SDS²⁰ and in ADNI.²¹ Genotype frequencies in both samples did not deviate from that predicted by Hardy-Weinberg equilibrium.

MRI (White matter hyperintensity volume)

SDS sample: MRI scans were acquired on a 1.5-Tesla Signa system (GE Healthcare, Milwaukee, WI). Three sets of structural MRI sequences were used: T1-weighted, T2-weighted, and proton-density weighted (PD). Details of MRI acquisition are provided elsewhere.¹⁵

MRIs were processed using the Semi-Automated Brain Region Extraction and Lesion Explorer processing pipeline.²² WMHs were identified as lesions that appear as punctate or diffuse regions of hyperintense signal on T2/PD MRI. These images were used to quantify global, deep and periventricular WMH volumes (cm³). For analyses, total WMH volumes adjusted for total intracranial volume (TIV) were used: TIV adjusted WMH volumes = (raw WMH volume/TIV) × 10³.

ADNI-I (Replication sample): Methods for MRI data acquisition, processing, and WMH quantification are described in detail elsewhere.²³

Neuropsychological test battery

SDS sample: The neuropsychological battery was performed within 90 days of MRI acquisition. Trained psychometrists blinded to neuroimaging, dementia diagnosis, and genotype information administered all tests.²⁴ The following tests for global cognition and domain specific functioning,

were administered: (1) Mini-Mental State Examination (MMSE), (2) Dementia Rating Scale (DRS), (3) California verbal Learning Test (CVLT), total acquisition score through five trials, CVLT long delay-free recall, and CVLT long delay-cued recall (4) Wechsler Memory Scale (WMS) visual recognition immediate and delayed recall, (5) forward digit span (FDS) (6) backward digit span (BDS), (7) Boston naming (BN) and (8) Semantic Fluency (SF), (9) Wisconsin Card Sorting test (WCST), (10) Controlled Oral Word Association task-Phonemic Fluency (PF-FAS), (11) Trail making test A, and (12) Digit Symbol substitution task (DSST). The number of patients who completed each test differed; this variability was dependent on dementia severity. 90% of patients had completed at least 8 neuropsychological tests.

ADNI-I (Replication sample): The cognitive test battery in ADNI-1 included (1) MMSE (2) Rey Auditory verbal learning test (RAVLT)-total acquisition score through five trials and delayed recall, (3) logical memory immediate and delayed recall, (4) FDS (5) BDS, (6) BN (7) category fluency (animals and vegetables), (8) Trail Making test A, and (9) DSST. Details are described elsewhere.²⁵

For all test scores, higher scores correspond to better cognition, except for WCST (number of non-perseverative errors; SDS only), and Trail making test A (time taken to complete the task in seconds), for which a higher score corresponds to worse performance.

Covariates

SDS sample: Age, sex, years of education, diabetes mellitus type 2 (present vs absent), systolic and diastolic blood pressure (mmHg), hypertension (present vs absent), smoking status (never,

past or current smoking), and dementia diagnosis (AD or DLB) were considered potential confounders.

ADNI-I (Replication sample): Available covariates in ADNI-I included age, sex, education, and systolic and diastolic blood pressure.

For consistency across both study samples, we included systolic and diastolic blood pressure as covariates and not hypertension.

Neuropathology methods in SDS (Exploratory sample)

36 of the SDS cases had a post-mortem neuropathological examination to diagnose and stage neurodegenerative disease phenomena.¹⁵ This workup included a screen for CAA using immunohistochemistry for beta-amyloid (Dako manufacturer, Mach 4 detection system) in at least two brain sections (cerebellum and frontal cortex). For 34 of these 36 cases, the original autopsy reports were reviewed by a neuropathologist (JK) to determine the presence or absence of CAA. For two of the 36 cases, the reports were not available. For three of the 34 cases with available reports, the presence or absence of amyloid angiopathy was not stated in the autopsy report; the slides from the original autopsy were retrieved, reviewed by JK, and the presence or absence of CAA was determined. Given that only two anatomical areas of the brain had been screened for CAA, applying a formal CAA grading scheme was not feasible. Using these data (n=34), we aimed to explore if there was a higher prevalence of CAA in *APOE*- ϵ 4 carriers.

Statistical analyses

TIV adjusted WMH volumes were log-transformed to achieve a normal distribution and standardized by calculating z-scores.

We compared participant characteristics between *APOE*- ϵ 4 carriers and non-carriers using *t*-tests for continuous and Chi-squared tests for categorical variables.

Confirmatory factor analysis and regression: In both samples, we aimed to reduce the number of tests by making comprehensive factor scores (latent constructs) for each cognitive domain, based on the specific tests and the domain that they are known to assess. Therefore, we conducted a Confirmatory Factor Analysis (CFA)²⁶ and calculated scores for each cognitive factor, i.e. attention/executive functions, learning/memory, and language for each participant. These cognitive factor scores were then used as outcomes in our analyses instead of individual test scores. CFA uses all available information for any model specified instead of a complete case analysis, and obtained factors are allowed to correlate. We present standardized parameters in this paper to facilitate interpretation. Adequacy of model fit to the data was assessed by Comparative fit index (CFI- range: 0-1; recommended ≥ 0.95), Root Mean Square Error of Approximation (RMSEA-range 0-1; recommended ≤ 0.06), and the Standardized Root Mean Square Residual (SRMR-range 0-1; recommended ≤ 0.08).²⁷

Subsequently, in both study samples, we first tested associations between WMH volume and each of the three cognitive factor scores with all covariates including *APOE*- ϵ 4 carrier status as a predictor, and also tested the interaction between WMH and *APOE*- ϵ 4 carrier status.

Second, we investigated the associations between WMH volume and each cognitive factor score in *APOE*- ϵ 4 carriers and non-carriers separately, based on our *a priori* hypothesis, i.e. higher

WMH burden would be more strongly associated with worse cognition in *APOE*- ϵ 4 carriers than non-carriers, because of the known strong biological effects of the *APOE*- ϵ 4 allele.²⁸

SDS sample: Relationships between the following cognitive factors and observed test scores were hypothesized and tested using CFA: (1) attention/executive functions [FDS, BDS, Trails A, WCST-perseverative errors, PF-FAS, and DSST], (2) learning/memory [CVLT-total acquisition score-trials 1-5, CVLT-long delay free and cued recall, WMS-immediate recall, and delayed recall], and (3) language [BN, SF, PF-FAS]. Scores for WCST and Trails A were inverse-coded for consistency with other test scores.

We used the following multiple linear regression model in the SDS sample ($N=289$) to test associations of WMH with executive functions, memory, and language, and an interaction between WMH and *APOE*- ϵ 4 carrier status:

$$\text{Cognitive factor score} = \beta_0 + \beta_1 * \text{WMH volume} + \beta_2 * \text{APOE-}\epsilon 4 \text{ carrier status} + \beta_3 * (\text{WMH volume} \times \text{APOE-}\epsilon 4 \text{ carrier status}) + \beta_4 * \text{age} + \beta_5 * \text{sex} + \beta_6 * \text{education} + \beta_7 * \text{diabetes mellitus} + \beta_8 * \text{systolic blood pressure} + \beta_9 * \text{diastolic blood pressure} + \beta_{10} * \text{smoking} + \beta_{11} * \text{clinical dementia diagnosis}$$

Further, we tested associations of WMH with the cognitive domains in *APOE*- ϵ 4 carriers and non-carriers separately using a similar model, but without *APOE*- ϵ 4 and its interaction term.

For each regression, two models were fitted. Model I was adjusted for age and sex; II was additionally adjusted for years of education, diabetes mellitus type 2, systolic and diastolic blood pressure, smoking status, and dementia diagnosis. We also repeated model II by replacing systolic and diastolic blood pressure by hypertension.

The following variables had missing values and were dealt with by multiple imputation using chained equations in Stata: systolic and diastolic blood pressure and smoking (2.8%, $n=8$), diabetes (3.1%, $n=9$), and years of education (0.3%, $n=1$). All available covariates were used as predictors for imputation.

Since studies suggest that WMH are not associated with cognition in DLB, but in AD only,^{4,29} we repeated the analyses in *APOE*- $\epsilon 4$ carriers and non-carriers excluding DLB cases.

In a *post-hoc* analysis, we tested if associations between WMH and cognitive domains in *APOE*- $\epsilon 4$ carriers were dependent on *APOE*- $\epsilon 4$ allele dosage. After comparing study characteristics and WMH volumes by *APOE*- $\epsilon 4$ allele dosage (0, 1 or 2 alleles) using ANOVA (*Tukey post-hoc*) and Chi-squared tests for continuous and categorical variables respectively, we repeated our analyses in *APOE*- $\epsilon 4$ heterozygotes ($n=130$) and *APOE*- $\epsilon 4$ homozygotes ($n=37$).

Exploratory neuropathology sample-SDS:

We explored the prevalence of CAA by *APOE*- $\epsilon 4$ carrier status in our autopsy subsample ($n=34$). This analysis was conditional on our primary results, i.e., to be performed if indeed WMH were associated with worse cognition more strongly in *APOE*- $\epsilon 4$ carriers than non-carriers. In this case, we hypothesized that since *APOE*- $\epsilon 4$ is a risk factor for CAA, the likely etiology of WMH in carriers is CAA which might be more toxic than WMH caused by vascular compromise or ischemia due to cardiovascular risk factors alone. We compared the numbers of patients with CAA by *APOE*- $\epsilon 4$ carrier status and by allele dosage using Fisher's exact test. Since studies suggest that CAA is more prevalent in *APOE*- $\epsilon 2$ carriers,³⁰ we also examined the number of persons with CAA across genotypes: $\epsilon 2$ - $\epsilon 3$ ($n=2$), $\epsilon 3$ - $\epsilon 3$ ($n=12$), $\epsilon 3$ - $\epsilon 4$ ($n=13$), and $\epsilon 4$ - $\epsilon 4$ ($n=7$), however, statistical comparisons could not be made due to small numbers within some cells.

ADNI-I (Replication sample): Relationships between the following cognitive factors and observed test scores were hypothesized and tested: (1) attention/executive [FDS, BDS, Trails making test A (inverse-coded), and DSST], (2) learning/memory [RAVLT-trials 1-5 (immediate recall), RAVLT-delayed recall, and logical memory immediate and delayed recall], and (3) language [BN, category fluency- animals, and category fluency-vegetables].

As in the SDS, a full model with and interaction term (WMH x *APOE*- ϵ 4) was tested (full ADNI-1 sample; $N=198$), and then analyses were repeated in *APOE*- ϵ 4 carriers and non-carriers separately. For regression, model I was adjusted for age and sex only; II was additionally adjusted for education, and systolic and diastolic blood pressure. Analyses were also repeated in *APOE*- ϵ 4 heterozygotes ($n=91$) and homozygotes ($n=40$).

Since power was limited in both our study samples, we meta-analyzed the beta-coefficients from SDS and ADNI-I for all three cognitive scores to obtain more robust estimates.³¹ This was done using the *metan* command in Stata,³² which uses inverse variance weighting method.

Level of significance was set at 0.05 (two-sided) for all statistical tests, and all analyses were performed using the Stata Software Version 14.1 (StataCorp, College Station, TX, USA).

Data availability statement

The authors have carefully documented all data, methods, and materials used to conduct the research in this article and agree to share anonymized data by request from any qualified investigator.

RESULTS

SDS sample

Characteristics of the study sample are presented in **Table 1**. Participant characteristics or WMH volumes did not differ between *APOE*- ϵ 4 carriers and non-carriers. **Table 2** summarizes the neuropsychological test scores by *APOE*- ϵ 4 carrier status.

In the CFA, single confirmatory factor models for all three cognitive factors tested showed excellent fit to the data: attention/executive (CFI=0.98; RMSEA=0.04; SRMR=0.03); learning/memory (CFI=0.99, RMSEA=0.04, SRMR=0.009); and language (CFI=1.00, RMSEA=<0.0001, SRMR= <0.0001).

In the full model ($N=289$), WMH volume was not associated with attention/executive functions, learning/memory or language. An interaction between WMH and *APOE*- ϵ 4 (p-value 0.02) was observed for language, but not for executive functions (p-value 0.26) or memory (p-value 0.11). With our *a priori* hypothesis that WMH relate to cognition differently in carriers and non-carriers, and a significant interaction observed between WMH and *APOE*- ϵ 4 for language, we performed analyses separately in *APOE*- ϵ 4 carriers and non-carriers for all cognitive domains.

In these analyses, greater WMH volumes were associated with worse attention/executive functions, learning/memory, and language in only *APOE*- ϵ 4 carriers; no associations were observed in non-carriers (**Table 3**). Replacing blood pressure with hypertension did not change results.

After excluding patients with DLB ($n=50$), a similar pattern of results was obtained (**Table 4**).

Homozygous *APOE*- ϵ 4 carriers were younger than non-carriers and heterozygous carriers (ANOVA p-value=<0.001). Homozygous *APOE*- ϵ 4 carriers also had lower WMH volume than

non-carriers and heterozygous carriers (ANOVA p-value =0.002). Heterozygous carriers had a greater burden of cardiovascular risk factors (**Table 1**). WMH were related to worse attention/executive functions (difference per SD: -0.23; 95% CI: -0.41, -0.04), learning /memory (difference per SD: -1.39; 95% CI: -2.51, -0.26), and language (difference per SD: -0.90; 95% CI: -1.59, -0.22) in *APOE-ε4* heterozygotes only, and not in homozygotes: (difference in attention/executive score per SD: 0.06; 95% CI: -0.37, 0.49; difference in learning/memory score per SD: 0.21; 95% CI: -2.21, 2.63; difference in language score per SD: 0.34; 95% CI: -2.14, 1.45).

Exploratory neuropathology sample-SDS:

In the autopsy subsample, 21 patients were neuropathologically diagnosed with AD and 15 with DLB. All AD cases were pathologically confirmed to have AD, including one case with coexisting Lewy bodies. All DLB cases were confirmed to have DLB, with varying degrees of neurofibrillary tangle pathology.¹⁵ 66.6% ($n=8/12$) of the *APOE-ε4* non-carriers had CAA compared to 76% ($n=16/21$) of *APOE-ε4* carriers. 64% ($n=9/14$) of heterozygous *APOE-ε4* carriers had CAA, whereas 100% ($n=7/7$) of the homozygous *APOE-ε4* carriers had CAA. However, differences across these groups were not significant (Fisher's exact test p-value=0.123). 50% ($n=6/12$) of patients with $ε3-ε3$ genotype had CAA, 50% ($n=1/2$) of the $ε3-ε2$ patients, 39% ($n=8/13$) of $ε3-ε4$ patients, and 100% ($n=7/7$) of the $ε4-ε4$ patients had CAA. There were no patients with $ε2-ε2$ genotype.

ADNI-I (Replication sample)

Characteristics of the study sample are summarized in **Table 5**. We did not find any differences in characteristics and WMH volumes between *APOE*- ϵ 4 carriers and non-carriers except that carriers were significantly younger than non-carriers (p-value 0.02).

Comparison of study characteristics by allele dosage showed that *APOE*- ϵ 4 homozygotes were younger than heterozygotes and non-carriers (ANOVA p-value= <0.001 ; **Table 5**). WMH volumes did not differ by allele-dosage. **Table 6** summarizes the neuropsychological test scores by *APOE*- ϵ 4 carrier status for ADNI-I.

In the CFA, single confirmatory factor models for all three cognitive factors tested, showed an excellent fit to the data: attention/executive (CFI=0.999, RMSEA= <0.0001 , SRMR=0.004); learning/memory (CFI=0.996, RMSEA=0.06, SRMR=0.019); language (CFI=1.00, RMSEA= <0.0001 , SRMR= <0.0001).

In the full model ($N=198$), WMH volume was associated with attention/executive functions (p-value <0.001), but not with memory or language. No interaction was observed between WMH and *APOE*- ϵ 4 for executive functions (p-value 0.069), memory (0.97), or language (0.34).

In *APOE*- ϵ 4 carriers only, greater WMH volume was associated with worse performance on the attention/executive functions and language, but not with memory (**Table 7**).

As in the SDS, WMH volume was associated with executive functions in *APOE*- ϵ 4 heterozygotes (difference per SD: -0.20; 95% CI: -0.30, -0.09) but not in homozygotes (difference in score: -0.23; 95% CI: -0.47, 0.002). For language, however, effect estimates for both homozygotes and heterozygotes were non-significant.

Meta-analyses of estimates from SDS and ADNI-I showed a strong association of WMH with attention/executive functions (difference per SD: -0.19; 95% CI: -1.27, -0.11; p-value: 2.117×10^{-3}), learning/memory (difference per SD: -1.02; 95% CI: -1.79, -0.25; p-value: 0.009) and language (difference per SD: -0.75; 95% CI: -1.19, -0.31; p-value: 0.0009) in carriers, with no effects seen in non-carriers. No heterogeneity was observed between the two studies and variance in effect-estimates attributable to heterogeneity for all domains was ~0%.

DISCUSSION

Our findings imply that in carriers of the *APOE*- ϵ 4 allele, WMH burden, a marker of cerebral SVD, is inversely associated with cognitive performance, whereas no such effect was seen in non-carriers. Moreover, this was consistent across the AD/DLB spectrum in contrast to previous studies.^{4,29} After excluding DLB patients from the SDS sample, the associations of WMH volume with executive functions, memory, and language remained significant. Cerebral SVD can be considered a relevant co-pathology across the AD/DLB spectrum. Because of the high frequency of coexisting neurodegenerative pathologies,^{33,34} shared risk factors and pathologies cannot be disentangled if samples are segregated on clinical diagnoses alone.¹⁵

Although a unified model with an interaction term is the optimum method to test effect-modification, an important limitation is that more statistical power is required than for association testing, and thus false negative results may be seen in smaller samples. The documented strong biological effects of *APOE*- ϵ 4²⁸ formed the basis of our *a priori* hypothesis, i.e. greater WMH burden relates more strongly with worse cognition in *APOE*- ϵ 4 carriers, which is why we also tested associations separately in carriers and non-carriers irrespective of the

interaction results. Given the strong biological rationale, limited sample size, and a significant interaction observed for the language domain, we believe that this was a valid approach, which has also been used by other groups.^{35,36} However, studies in larger sample sizes are warranted.

The replication of worse executive functions and language in relation to higher WMH in ADNI-I *APOE-ε4* carriers, is remarkable, and also validates our findings. Notably, ADNI-I comprises cases with relatively lower WMH burden compared to SDS,¹⁷ and this finding indicates that *APOE-ε4* may contribute to worse cognitive performance in those with even a lower burden of cerebral SVD. Effect estimates for memory did not reach significance in the ADNI-I sample which might be explained by lack of power. However, the significant association of greater WMH volume with cognitive impairment across all three domains observed in the meta-analysis supports our primary findings.

While our data supported our hypothesis, it failed to show an allele dosage effect. This could be a result of the small size of the homozygous group; however, the similar pattern of results in both SDS and ADNI-I suggests that this is not just a power issue. There are several possible considerations. The first consideration is age and cardiovascular risk factor distribution.

Although in both study samples, age did not differ between *APOE-ε4* carriers and non-carriers; among carriers, homozygotes were younger. In the SDS sample, the homozygous group was not only younger, but it also had less WMH and cardiovascular risk factor burden, which might explain our findings. Second, since we adjusted for these pertinent confounders, a complex interaction may exist between *APOE-ε4*, vascular risk factors, WMH, and cognition.^{37,38}

Specifically, a higher vascular risk factor burden combined with *APOE-ε4* genotype results in reduced white matter integrity and predicts faster cognitive decline.³⁸ Third, the observed association might also be dependent on the disease stage in addition to age, such that the

association of WMH and cognition becomes more apparent with advancing age and dementia progression.³⁹ Increasing age becomes an important determinant of cognitive decline when effects of *APOE-ε4* and its interactions with other risk factors are at play.^{40,41}

The mechanisms underlying this association may be Amyloid-beta ($A\beta$) dependent, $A\beta$ independent, or both. In addition to causing accelerated cerebral amyloid deposition and impaired clearance of $A\beta$, *APOE-ε4* can cause detrimental effects on brain through vascular pathways. *APOE-ε4* is associated with neurovascular dysfunction, has a synergistic effect with atherosclerosis by disrupting cholesterol homeostasis, and also affects vessels via CAA. These synergistic effects can drastically compound the damaging effects of WMH in *APOE-ε4* carriers.⁴² Faster WMH progression rates were noted in *APOE-ε4* positive AD patients and healthy adults, supporting our interaction hypothesis.^{39,43} *APOE-ε4* carriers might also have more covert WM damage which is not detected by routine imaging,⁴⁴ but is reflected as worse cognitive outcomes. Future large prospective studies are needed.

WMH burden reflects a worse cerebrovascular status, potentially increasing vulnerability to neurodegeneration. Higher WMH volume has been associated with reduced cerebral perfusion both in hyperintense areas and normal appearing white matter.⁴⁵ Normal appearing white matter surrounding WMH already exhibit subtle damage,⁴⁴ and will likely develop into areas of T2 MRI-detectable WMH. Also, neuroinflammation is a key feature in AD,⁴⁶ and *APOE-ε4* carriers have increased levels of plasma inflammatory markers compared to non-carriers, and may also have a differential regulation of neuroinflammatory responses compared to other *APOE* isoforms.^{47,48} WMH might be a consequence of neuroinflammation.⁴⁹

Our neuropathology data showed high agreement between our clinical diagnosis and the definitive pathological diagnosis. Although our data showed that 100% of homozygous *APOE-ε4* carriers had CAA compared to 64% of heterozygotes, it did not show that WMH burden was associated with worse cognition in people with two alleles, and should be interpreted with caution due to the small sample size. While we cannot deduce that worse cognitive outcomes in *APOE-ε4* carriers with WMH are due to CAA, we can speculate that CAA is the more likely etiology for WMH in *APOE-ε4* carriers than in non-carriers, or the likelihood of CAA increases with each added *APOE-ε4* allele. The accelerated amyloid deposition in *APOE-ε4* carriers together with CAA may have a multiplicative detrimental effect on cognition. Findings from a recent population-based study concur with our data showing accelerated WMH-related decline in MMSE score in *APOE-ε4* carriers only. However, this study employed a microvascular lesion load summary score, which ranked an individual from 0 to 3 based on the absence or presence of WMH volume, lacunes and perivascular spaces beyond a predefined cut-off. Additionally, this study did not examine the effects of *APOE-ε4* allele dosage on the associations of microvascular lesion load and MMSE. Therefore, comparisons to our results in this regard could not be made.⁵⁰ In contrast, we used quantitative WMH volume as a continuous predictor and three cognitive domains as outcomes rather than global cognitive score in our study.

We examine the effect of *APOE-ε4* on the association between WMH and cognition in the two most common neurodegenerative dementia diagnoses, i.e. AD and DLB, which is uncommon as most studies focus on AD. Strengths of our study include a well characterized study sample of dementia patients, rigorous image-processing methods validated for older adults and mixed dementias, comprehensive neuropsychological testing, adjusting for confounders, use of an autopsy confirmed subset of data, and replication of findings in an independent dataset.

However, there are certain limitations. This was a cross-sectional study and therefore causal inferences could not be deduced. The statistical tests in some sub-analyses, such as those in homozygous *APOE*- ϵ 4 carriers and the autopsy sub-sample, had limited power to detect associations, and the null association in the non-carriers of *APOE*- ϵ 4 might be a result of the limited sample size (power) as well. Therefore, studies with larger sample sizes are required. However, in an attempt to obtain more robust estimates, we conducted meta-analyses of estimates from SDS and ADNI, which resulted in stronger results. The SDS and ADNI-I used a different neuropsychological battery; however, there were similar tests available in both cohorts tapping into the major cognitive domains. This would not have affected our results as replication is more robust if performed using a different methodology to test the same research question. The number of patients who completed each cognitive test differed, which was related to dementia severity. Missing data from more severe cases might have resulted in an underestimation of the associations. Smoking and diabetes were not documented for most ADNI-I participants, hence were not included as covariates; these were not significant confounders in the SDS sample, so we believe models in the two samples are fairly comparable. The numbers in the autopsy-based dataset were not sufficient to draw definitive conclusions; however they provided important insights and can possibly direct future research.

APOE- ϵ 4 may influence the association of WMH with executive functions and language across the spectrum of AD and DLB. Our meta-analysis results showed significant associations of greater WMH volume with cognitive impairment across all three cognitive domains tested. Information about the *APOE*- ϵ 4 status of patients may be useful to understand the relative contributions of different pathologies to an individual's unique dementia syndrome, and to guide therapy as well. Future studies should aim to extend these findings to other dementia diagnoses

and larger datasets. These findings emphasize the importance of WMH (as a marker of SVD) across the AD/DLB spectrum, and open avenues for further research to understand shared etiologies and risk factors across the dementias.

ACKNOWLEDGEMENTS

The authors thank the participants, their relatives, psychometric assessors, and examiners who contributed to the Sunnybrook Dementia Study since its inception. The authors are grateful to Melissa Holmes and Christopher Scott for their assistance in imaging database queries and technical support. The authors are also thankful to Alicia McNeely and Courtney Berezuk for assistance in image processing, Isabel Lam for helping with clinical database queries, Dr. Fuqiang Gao for providing radiological expertise for the identification and exclusion of strokes, and Dr. Fadi Frankul for help in compiling the autopsy results. The authors also gratefully acknowledge financial support from the following sources: M.M. receives salary support from the Department of Medicine at Sunnybrook Health Sciences Centre and the University of Toronto, as well as the Sunnybrook Research Institute. S.S.M receives salary support from Alzheimer's Society Canada, and Canadian Institutes of Health Research-Strategic Training in Genetic Epidemiology (STAGE). W.S. reports support from the Alzheimer's Association (US) and Brain Canada (AARG501466). U.S. was supported by Ontario Graduate Scholarship, Margaret & Howard Gamble Research Grant, and Scace Graduate Fellowship in Alzheimer's Research, University of Toronto.

The authors report no conflicts of interest with the work presented in this study.

ADNI acknowledgements:

Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at:

http://adni.loni.usc.edu/wpcontent/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and

Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

REFERENCES

1. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. *Lancet Neurol.* 2010;9(7):689-701. doi:10.1016/S1474-4422(10)70104-6.
2. Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an update. *Nat Rev Neurol.* 2015;11(3):157-165. doi:10.1038/nrneurol.2015.10.
3. Cai Z, Wang C, He W, et al. Cerebral small vessel disease and Alzheimer's disease. *Clin Interv Aging.* 2015;10:1695. doi:10.2147/CIA.S90871.
4. Oppedal K, Aarsland D, Firbank MJ, et al. White matter hyperintensities in mild lewy body dementia. *Dement Geriatr Cogn Dis Extra.* 2012;2(1):481-495. doi:10.1159/000343480.
5. Sarro L, Tosakulwong N, Schwarz CG, et al. An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. *Alzheimers Dement.* 2017;13(3):257-266. doi:10.1016/j.jalz.2016.07.003.
6. Ovbiagele B, Saver JL. Cerebral white matter hyperintensities on MRI: Current concepts and therapeutic implications. *Cerebrovasc Dis.* 2006;22(2-3):83-90. doi:10.1159/000093235.
7. Sandeman EM, Hernandez M del CV, Morris Z, et al. Incidental Findings on Brain MR Imaging in Older Community-Dwelling Subjects Are Common but Serious Medical Consequences Are Rare: A Cohort Study. Sathian K, ed. *PLoS One.* 2013;8(8):e71467. doi:10.1371/journal.pone.0071467.

8. Black S, Gao F, Bilbao J. Understanding White Matter Disease: Imaging-Pathological Correlations in Vascular Cognitive Impairment. *Stroke*. 2009;40(3, Supplement 1):S48-S52. doi:10.1161/STROKEAHA.108.537704.
9. Keith J, Gao F, Noor R, et al. Collagenosis of the Deep Medullary Veins: An Underrecognized Pathologic Correlate of White Matter Hyperintensities and Periventricular Infarction? *J Neuropathol Exp Neurol*. 2017;76(4):299-312. doi:10.1093/jnen/nlx009.
10. Wardlaw JM, Valdés Hernández MC, Muñoz-Maniega S. What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. *J Am Heart Assoc*. 2015;4(6):1140. doi:10.1161/JAHA.114.001140.
11. Tsuang D, Leverenz JB, Lopez OL, et al. APOE ϵ 4 Increases Risk for Dementia in Pure Synucleinopathies. *JAMA Neurol*. 2013;70(2):223. doi:10.1001/jamaneurol.2013.600.
12. Bras J, Guerreiro R, Darwent L, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. *Hum Mol Genet*. 2014;23(23):6139-6146. doi:10.1093/hmg/ddu334.
13. Schilling S, DeStefano AL, Sachdev PS, et al. APOE genotype and MRI markers of cerebrovascular disease: systematic review and meta-analysis. *Neurology*. 2013;81(3):292-300. doi:10.1212/WNL.0b013e31829bfda4.
14. Høgh P, Garde E, Mortensen EL, Jørgensen OS, Krabbe K, Waldemar G. The apolipoprotein E ϵ 4-allele and antihypertensive treatment are associated with increased risk of cerebral MRI white matter hyperintensities. *Acta Neurol Scand*. 2007;115(4):248-

253. doi:10.1111/j.1600-0404.2006.00779.x.
15. Saeed U, Mirza SS, MacIntosh BJ, et al. APOE -ε4 associates with hippocampal volume, learning, and memory across the spectrum of Alzheimer's disease and dementia with Lewy bodies. *Alzheimer's Dement.* May 2018. doi:10.1016/j.jalz.2018.04.005.
 16. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. *Neurology.* 2010;74(3):201-209.
doi:10.1212/WNL.0b013e3181cb3e25.
 17. Ramirez J, McNeely AA, Scott CJM, Masellis M, Black SE, Alzheimer's Disease Neuroimaging Initiative. White matter hyperintensity burden in elderly cohort studies: The Sunnybrook Dementia Study, Alzheimer's Disease Neuroimaging Initiative, and Three-City Study. *Alzheimer's Dement.* 2016;12(2):203-210.
doi:10.1016/j.jalz.2015.06.1886.
 18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology.* 34(7):939-944.
 19. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. *Neurology.* 65(12):1863-1872.
 20. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. *Neurology.* 1993;43(8):1467-1472. <http://www.ncbi.nlm.nih.gov/pubmed/8350998>. Accessed March

- 1, 2017.
21. Saykin AJ, Shen L, Yao X, et al. Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. *Alzheimers Dement*. 2015;11(7):792-814. doi:10.1016/j.jalz.2015.05.009.
 22. Ramirez J, Scott CJ, McNeely AA, et al. Lesion Explorer: a video-guided, standardized protocol for accurate and reliable MRI-derived volumetrics in Alzheimer's disease and normal elderly. *JVisExp*. 2014;(86).
 23. Schwarz C, Fletcher E, DeCarli C, Carmichael O. Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR. *Inf Process Med Imaging*. 2009;21:239-251. <http://www.ncbi.nlm.nih.gov/pubmed/19694267>. Accessed July 11, 2018.
 24. Misch MR, Mitchell S, Francis PL, et al. Differentiating between visual hallucination-free dementia with Lewy bodies and corticobasal syndrome on the basis of neuropsychology and perfusion single-photon emission computed tomography. *AlzheimersResTher*. 2014;6(9):71-.
 25. Park LQ, Gross AL, McLaren DG, et al. Confirmatory factor analysis of the ADNI Neuropsychological Battery. *Brain Imaging Behav*. 2012;6(4):528-539. doi:10.1007/s11682-012-9190-3.
 26. Norman Geoffrey R. SDL. PDQ Statistics. In: *PDQ Statistics* . Third. Waslworth Printing Comapny; 2003. https://books.google.ca/books?id=huoPAHPkxVYC&pg=PA21&source=gbs_selected_pa

- ges&cad=2#v=onepage&q=factor analysis&f=false. Accessed July 9, 2018.
27. Hu L, Bentler PM. Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. *Struct Equ Model A Multidiscip J*. 1999;6(1):1-55. doi:10.1080/10705519909540118.
 28. Zlokovic B V. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. *JAMA Neurol*. 2013;70(4):440-444. doi:10.1001/jamaneurol.2013.2152.
 29. Sarro L, Tosakulwong N, Schwarz CG, et al. An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. *Alzheimer's Dement*. 2017;13(3):257-266. doi:10.1016/J.JALZ.2016.07.003.
 30. McCarron MO, Nicoll JA. Apolipoprotein E genotype and cerebral amyloid angiopathy-related hemorrhage. *Ann N Y Acad Sci*. 2000;903:176-179.
<http://www.ncbi.nlm.nih.gov/pubmed/10818505>. Accessed July 13, 2018.
 31. Peterson RA, Brown SP. On the Use of Beta Coefficients in Meta-Analysis. *Psychol Assoc*. 2005;90(1):175-181. doi:10.1037/0021-9010.90.1.175.
 32. Harris RJ, Deeks JJ, Altman DG, Bradburn MJ, Harbord RM, Sterne JAC. Metan: Fixed- and Random-Effects Meta-Analysis. *Stata J Promot Commun Stat Stata*. 2008;8(1):3-28. doi:10.1177/1536867X0800800102.
 33. Schneider JA, Arvanitakis Z, Bang W, Bennett DA, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. *Neurology*. 2007;69(24):2197-2204. doi:10.1212/01.wnl.0000271090.28148.24.
 34. Rahimi J, Kovacs GG. Prevalence of mixed pathologies in the aging brain. *Alzheimers Res*

- Ther.* 2014;6(9):82. doi:10.1186/s13195-014-0082-1.
35. Qian J, Wolters FJ, Beiser A, et al. APOE-related risk of mild cognitive impairment and dementia for prevention trials: An analysis of four cohorts. *PLoS Med.* 2017;14(3):e1002254. doi:10.1371/journal.pmed.1002254.
 36. Nyarko JNK, Quartey MO, Pennington PR, et al. Profiles of β -Amyloid Peptides and Key Secretases in Brain Autopsy Samples Differ with Sex and APOE ϵ 4 Status: Impact for Risk and Progression of Alzheimer Disease. *Neuroscience.* 2018;373:20-36. doi:10.1016/J.NEUROSCIENCE.2018.01.005.
 37. Yoon B, Shim YS, Cheong H-K, et al. Interaction of white matter hyperintensities (WMHs) and apolipoprotein E (APOE) genotypes on cognition in patients with amnesic mild cognitive impairment (aMCI). *Arch Gerontol Geriatr.* 2013;57(3):292-297. doi:10.1016/J.ARCHGER.2013.04.008.
 38. Wang R, Fratiglioni L, Laukka EJ, et al. Effects of vascular risk factors and APOE ϵ 4 on white matter integrity and cognitive decline. *Neurology.* 2015;84(11):1128-1135. doi:10.1212/WNL.0000000000001379.
 39. Sudre CH, Cardoso MJ, Frost C, et al. APOE ϵ 4 status is associated with white matter hyperintensities volume accumulation rate independent of AD diagnosis. *Neurobiol Aging.* 2017;53:67-75. doi:10.1016/J.NEUROBIOLAGING.2017.01.014.
 40. Christensen H, Batterham PJ, Mackinnon AJ, et al. The association of APOE genotype and cognitive decline in interaction with risk factors in a 65-69 year old community sample. *BMC Geriatr.* 2008;8:14. doi:10.1186/1471-2318-8-14.

41. Rawle MJ, Davis D, Bendayan R, Wong A, Kuh D, Richards M. Apolipoprotein-E (ApoE) $\epsilon 4$ and cognitive decline over the adult life course. *Transl Psychiatry*. 2018;8(1):18. doi:10.1038/s41398-017-0064-8.
42. Liu C-C, Kanekiyo T, Xu H, Bu G, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. *Nat Rev Neurol*. 2013;9(2):106-118. doi:10.1038/nrneurol.2012.263.
43. Luo X, Jiaerken Y, Yu X, et al. Associations between APOE genotype and cerebral small-vessel disease: a longitudinal study. *Oncotarget*. 2017;8(27):44477-44489. doi:10.18632/oncotarget.17724.
44. de Groot M, Verhaaren BFJ, de Boer R, et al. Changes in Normal-Appearing White Matter Precede Development of White Matter Lesions. *Stroke*. 2013;44(4):1037-1042. doi:10.1161/STROKEAHA.112.680223.
45. Promjunyakul N, Lahna D, Kaye JA, et al. Characterizing the white matter hyperintensity penumbra with cerebral blood flow measures. *NeuroImage Clin*. 2015;8:224-229. doi:10.1016/j.nicl.2015.04.012.
46. Broussard GJ, Mytar J, Li R, Klapstein GJ. The role of inflammatory processes in Alzheimer's disease. *Inflammopharmacology*. 2012;20(3):109-126. doi:10.1007/s10787-012-0130-z.
47. Ringman JM, Elashoff D, Geschwind DH, et al. Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype. *Arch Neurol*. 2012;69(6):757-764. doi:10.1001/archneurol.2012.277.

48. Salvarani C, Hunder GG, Morris JM, et al. A β -related angiitis: comparison with CAA without inflammation and primary CNS vasculitis. *Neurology*. 2013;81(18):1596-1603. doi:10.1212/WNL.0b013e3182a9f545.
49. Zhu Y, Chai YL, Hilal S, et al. Serum IL-8 is a marker of white-matter hyperintensities in patients with Alzheimer's disease. *Alzheimer's Dement Diagnosis, Assess Dis Monit*. 2017;7:41-47. doi:10.1016/j.dadm.2017.01.001.
50. Wang R, Laveskog A, Laukka EJ, et al. MRI load of cerebral microvascular lesions and neurodegeneration, cognitive decline, and dementia. *Neurology*. 2018;91(16):1. doi:10.1212/WNL.0000000000006355.

Table 1: Characteristics of the study sample, N=289 (Sunnybrook Dementia Study)

Characteristics	Descriptives				
	Total sample N=289 (122+167)	<i>APOE</i> - ϵ 4 non- carriers n=122	<i>APOE</i> - ϵ 4 carriers n=167	Carriers of 1 <i>APOE</i> - ϵ 4 allele n=130	Carriers of 2 <i>APOE</i> - ϵ 4 alleles n=37
Age (years)	71.1 (9.6)	71.7 (10.5)	70.7 (8.9)	71.1 (9.2)	69.4 (7.7)
Women	147 (50.9)	57 (46.7)	90 (53.9)	70 (53.8)	20 (54.0)
Educational level (years)	13.9 (3.6)	13.9 (3.6)	13.9 (3.6)	14.1 (3.5)	13.2 (3.9)
MMSE score	23.5 (4.1)	23.5 (4.3)	23.6 (4.0)	23.6 (4.0)	23.5 (3.9)
DRS score	118.8 (13.4)	118.5 (14.4)	119.0 (12.8)	119.0 (13.0)	120.2 (12.1)
Smoking					
Never	168 (58.1)	69 (56.6)	99 (59.3)	74 (56.9)	25 (67.6)
Former	104 (36.0)	49 (40.2)	55 (32.9)	45 (34.6)	10 (27.0)
Current	17 (5.9)	4 (3.3)	13 (7.8)	11 (8.5)	2 (5.4)
Systolic blood pressure, mmHg	138.3 (19.7)	135.8 (20.9)	140.1 (18.6)	140.9 (19.1)	137.2 (16.2)
Diastolic blood pressure, mmHg	80.4 (10.3)	80.4 (10.4)	80.1 (9.7)	79.8 (9.6)	80.0 (9.3)

Hypertension	101 (35.0)	50 (41.0)	51 (30.1)	44 (33.8)	6 (16.2)
Diabetes mellitus type 2	25 (8.6)	12 (9.8)	13 (7.8)	13 (10)	0 #
Clinical diagnosis of dementia					
AD + varying SVD	239 (82.7)	100 (82.0)	139 (83.2)	110 (84.6)	29 (78.4)
DLB + varying SVD	50 (17.3)	22 (18.0)	28 (16.8)	20 (15.4)	8 (21.6)
Raw WMH, cm ³	7.5 (10.4)	8.1 (10.4)	7.2 (10.4)	7.5 (10.6)	6.1 (9.5)
TIV adjusted WMH	6.2 (8.4)	6.7 (8.8)	5.8 (8.1)	6.0 (7.9)	5.3 (8.8)
TIV adjusted WMH, median [IQR]	3.1 [1.1-8.1]	3.3 [1.1-8.5]	3.0 [1.0-7.8]	3.4 [1.1-8.5]	2.2 [0.9-5.6]

Values are means (standard deviation), counts (percentage), or medians [interquartile range]

Abbreviations: MMSE-Mini-Mental State examination; DRS-Dementia Rating Scale; AD-Alzheimer's disease; SVD-Small vessel disease; DLB-Dementia with Lewy bodies; TIV-Total intracranial volume; IQR- interquartile range

Table 2: Summary of cognitive test battery in the Sunnybrook Dementia Study

Neuropsychological Test	n	Recorded response (maximum score)	Mean Score \pm SD (range)	
			<i>APOE-ϵ4 non-carriers</i>	<i>APOE-ϵ4 carriers</i>
<i>Global cognition</i>				
MMSE	289	Score (30)	23.6 \pm 4.2 (10-30)	23.8 \pm 3.9 (11-30)
Dementia Rating Scale	289	Total score (144)	118.4 \pm 14.4 (49-143)	119.1 \pm 12.8 (82-141)
<i>Attention/Executive function</i>				
Forward Digit Span	289	Number of digits correctly repeated (12)	7.5 \pm 2.1 (3-12)	7.8 \pm 2.3 (2-12)
Backward Digit Span	289	Number of digits correctly repeated (12)	4.6 \pm 2.0 (0-10)	5.3 \pm 2.2 (0-11)
Trail making Test A	223	Time taken to complete the task (seconds)	90.6 \pm 83.8 (22-559)	86.4 \pm 65.4 (25-310)
WCST	246	Number of non-perseverative errors	12.7 \pm 12.4 (1-48)	14.7 \pm 13.0 (0-47)
Phonemic fluency	236	No of correct responses (words listed starting with letters F-A-S in 1 minute)	25.4 \pm 12.7 (1-73)	29.5 \pm 13.9 (3-76)
Digit Symbol Substitution Task	201	Number of correct matches (133)	30.4 \pm 14.1 (2-65)	31.7 \pm 13.8 (1-62)
<i>Learning/Memory</i>				
CVLT 1-5	272	Total number of words correctly recalled across five trials (75)	22.8 \pm 9.8 (4-67)	22.0 \pm 9.8 (0-50)
CVLT-Long delay free recall	259	Number of words correctly recalled after 20 minutes (15)	2.3 \pm 2.8 (0-13)	1.7 \pm 2.3 (0-10)

CVLT-Long delay cued recall	259	Number of words correctly recalled after 20 minutes with cuing (15)	3.7±2.9 (0-14)	3.2±2.7 (0-11)
WMS-visual reproduction- immediate recall	265	Number of correct responses (41)	17.7±7.7 (0-34)	17.3±7.6 (1-35)
WMS-visual reproduction- delayed recall	263	Number of correct responses after a delay (41)	3.9±5.3 (0-20)	3.1±5.0 (0-22)
<i>Language</i>				
Boston Naming	289	The number of spontaneous correct (30)	21.3±6.3 (0-30)	21.5±6.3 (4-30)
Semantic Fluency	289	Number of correct responses in one minute (animal names)	10.4±4.7 (0-26)	10.9±5.1 (0-34)

Abbreviations: MMSE: Mini Mental State Examination; CVLT: California Verbal Learning Test; WMS: Wechsler Memory Scale; WCST: Wisconsin Card Sorting Test

Table 3: Association between white matter hyperintensities volume and factor scores by *APOE*- ϵ 4 carrier status—the Sunnybrook Dementia Study

Association between WMH and cognition								
Factor	<i>APOE</i> - ϵ 4 non-carriers, <i>n</i> =122				<i>APOE</i> - ϵ 4 carriers, <i>n</i> =167			
	Model 1		Model 2		Model 1		Model 2	
	Difference per SD (95% CI)	P-value	Difference per SD (95% CI)	P-value	Difference per SD (95% CI)	P-value	Difference per SD (95% CI)	P-value
Attention/Executive	-0.01 (-0.19, 0.16)	0.883	0.01 (-0.10, 0.23)	0.895	-0.16 (-0.33, 0.01)	0.071	-0.18 (-0.35, -0.01)	0.034
Learning/Memory	-0.23 (-1.57, 1.11)	0.732	-0.28 (-1.69, 1.14)	0.699	-0.97 (-1.94, 0.005)	0.051	-1.07 (-2.07, -0.08)	0.034
Language	0.15 (-0.53, 0.84)	0.653	0.17 (-0.53, 0.86)	0.634	-0.82 (-1.44, -0.19)	0.011	-0.86 (-1.51, -0.21)	0.009

Model 1: adjusted for age and sex only

Model 2: additionally adjusted for education, systolic and diastolic blood pressure, diabetes mellitus type 2, smoking status, and the clinical diagnosis of dementia

Factor scores are derived from Confirmatory Factor Analysis. Tests constituting the factor scores are as follows:

Attention/executive: Forward and backward digit span, Wisconsin Card Sorting Test (reverse coded), phonemic fluency F-A-S, trails making test A (reverse coded), and digit symbol substitution task

Learning/memory: California verbal Learning test (CVLT) 1-5, CVLT long delay free and cued recall, and Wechsler memory scale visual recognition immediate and delayed recall

Language: Boston naming, semantic fluency, and phonemic fluency F-A-S

Table 4: Association between white matter hyperintensities volume and factor scores by *APOE-ε4* carrier status after excluding DLB cases—the Sunnybrook Dementia Study

Association between WMH and cognition								
Factor	<i>APOE-ε4</i> non-carriers, <i>n</i> =100				<i>APOE-ε4</i> carriers, <i>n</i> =139			
	Model 1		Model 2		Model 1		Model 2	
	Difference per SD (95% CI)	P-value	Difference per SD (95% CI)	P-value	Difference per SD (95% CI)	P-value	Difference per SD (95% CI)	P-value
Attention/Executive	0.01 (-0.18, 0.19)	0.941	0.02 (-0.17, 0.21)	0.835	-0.18 (-0.37, 0.01)	0.060	-0.20 (-0.39, -0.005)	0.044
Learning/Memory	-0.14 (-1.58, 1.30)	0.848	-0.15 (-1.69, 1.39)	0.848	-1.14 (-2.22, -0.06)	0.038	-1.21 (-2.31, -0.11)	0.031
Language	0.15 (-0.60, 0.90)	0.688	0.19 (-0.60, 0.98)	0.633	-1.00 (-1.70, -0.31)	0.005	-1.06 (-1.78, -0.35)	0.004

Model 1: adjusted for age and sex only

Model 2: additionally adjusted for education, systolic and diastolic blood pressure, diabetes mellitus type 2, and smoking

Factor scores are derived from Confirmatory Factor Analysis. Tests constituting the factor scores are as follows:

Attention/executive: Forward and backward digit span, Wisconsin Card Sorting Test (reverse coded), phonemic fluency F-A-S, trails making test A (reverse coded), and digit symbol substitution task

Learning/memory: California verbal Learning test (CVLT) 1-5, CVLT long delay free and cued recall, and Wechsler memory scale
visual recognition immediate and delayed recall

Language: Boston naming, semantic fluency, and phonemic fluency F-A-S

Table 5: Study sample characteristics-Alzheimer's Disease Neuroimaging Initiative (ADNI-1)

Characteristics	Descriptives				
	Total sample N=198 (67+131)	<i>APOE</i> - ϵ 4 non- carriers n=67	<i>APOE</i> - ϵ 4 carriers n=131	Carriers of 1 <i>APOE</i> - ϵ 4 allele n=91	Carriers of 2 <i>APOE</i> - ϵ 4 alleles n=40
Age (years)	75.1 (7.4)	76.8 (8.6)	74.3 (6.5)	75.4 (6.1)	71.8 (6.9)
Women	84 (42.0)	34 (50.7)	50 (37.6)	40 (44.4)	16 (45.7)
Educational level (years)	15.3 (3.0)	15.4 (3.2)	15.2 (2.9)	15.1 (3.1)	15.3 (2.4)
MMSE score	20.7 (4.9)	20.9 (5.2)	20.7 (4.8)	20.7 (4.6)	20.5 (5.4)
Systolic blood pressure, mmHg	133.7 (18.1)	132.7 (20.6)	134.2 (16.7)	134.1 (15.9)	134.5 (18.5)
Diastolic blood pressure, mmHg	73.5 (10.4)	72.2 (11.4)	74.1 (9.8)	73.8 (10.0)	74.8 (9.5)
TIV adjusted WMH	0.8 (1.5)	1.1 (2.0)	0.72 (1.2)	0.76 (1.3)	0.66 (1.1)
TIV adjusted WMH , median [IQR]	0.31 [0.12-0.78]	0.31[0.11-0.99]	0.32[0.12-0.73]	0.28 [0.12-0.60]	0.32 [0.11-0.87]

Values are means (standard deviation) or counts (percentage) or medians [interquartile range]

Abbreviations: MMSE-Mini-Mental State examination, SD-standard deviation; IQR-interquartile range

Table 6: Summary of cognitive test battery in the ADNI-I study

Neuropsychological Test	n	Recorded response (maximum score)	Mean Score \pm SD (range)	
			<i>APOE-ϵ4 non-carriers</i>	<i>APOE-ϵ4 carriers</i>
<i>Global cognition</i>				
MMSE	198	Score (30)	20.9 \pm 5.2 (5-30)	20.7 \pm 4.8 (5-28)
<i>Attention/Executive function</i>				
Forward Digit Span	198	Number of digits correctly repeated (14)	6.8 \pm 2.7 (0-12)	6.9 \pm 2.1 (0-12)
Backward Digit Span	198	Number of digits correctly repeated (14)	4.4 \pm 2.1 (0-8)	4.8 \pm 2.0 (1-11)
Trail making Test A	198	Time taken to complete the task (seconds)	71.9 \pm 42.4 (27-150)	67.6 \pm 40.2 (0-150)
Digit Symbol Substitution Task	198	Number of correct digit symbol matches (133)	25.1 \pm 14.9 (0-53)	24.2 \pm 13.9 (0-56)
<i>Learning/Memory</i>				
RAVLT1-5	198	Total number of words correctly recalled across five trials (75)	19.8 \pm 8.9 (0-38)	18.9 \pm 8.1 (0-36)
RAVLT-delayed recall	198	Total number of words correctly recalled after a 20 minute delay (15)	6.9 \pm 4.6 (0-15)	5.2 \pm 4.1 (0-15)
Logical Memory-immediate recall	198	Total bits of information from the story recalled immediately (25)	4.0 \pm 3.3 (0-17)	3.7 \pm 3.2 (0-13)
Logical Memory-delayed recall	198	Total bits of information from the story recalled after a 30-minute delay (25)	1.3 \pm 2.7 (0-14)	0.9 \pm 2.0 (0-10)
<i>Attention and working memory</i>				

Language

Boston Naming	198	The number of spontaneous correct (30)	21.0±8.0 (0-30)	21.1±7.1 (2-30)
Category Fluency-animals	198	Number of correct responses in one minute (animal names)	10.6±5.4 (0-37)	11.3±5.4 (1-27)
Category Fluency-vegetables	198	Number of correct responses in one minute (vegetable names)	7.1±3.8 (0-17)	6.4±4.0 (0-19)

Abbreviations: MMSE: Mini Mental State Examination; RAVLT: Rey Auditory Verbal Learning Test

Table 7: Association between white matter hyperintensities volume and factor scores obtained by confirmatory factor analyses, the Alzheimer’s Disease Neuroimaging Initiative Phase I—ADNI-I

Association between WMH and cognition								
Factor	<i>APOE-ε4</i> non-carriers, n=67				<i>APOE-ε4</i> carriers, n=131			
	Model 1		Model 2		Model 1		Model 2	
	Difference per SD (95% CI)	P-value	Difference per SD (95% CI)	P-value	Difference per SD (95% CI)	P-value	Difference per SD (95% CI)	P-value
Attention/Executive	-0.10 (-0.22, 0.02)	0.101	-0.09 (-0.10, 0.08)	0.147	-0.19 (-0.28, -0.10)	<0.001	-0.19 (-0.28, -0.10)	<0.001
Learning/Memory	-1.37 (-3.24, 0.50)	0.148	-1.27 (-3.21, 0.67)	0.196	-0.82 (-2.09, 0.45)	0.204	-0.94 (-2.19, 0.31)	0.138
Language	-0.32 (-1.10, 0.46)	0.420	-0.29 (-1.10, 0.51)	0.467	-0.60 (-1.21, 0.01)	0.055	-0.65 (-1.26, -0.03)	0.040

Model 1: adjusted for age and sex only

Model 2: additionally adjusted for education, and systolic and diastolic blood pressure

Factor scores are derived from Confirmatory Factor Analysis. Tests constituting the factor scores are as follows:

Attention/executive: Forward and backward digit span, trails making test A (reverse coded), and digit symbol substitution task

Learning/memory: Rey Auditory Verbal Learning Test (RAVLT) score through trials 1-5, RAVLT delayed recall, Logical memory immediate and delayed recall

Language: Boston naming, category fluency animals, and category fluency vegetables